REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
4 hedge funds and large institutions have $48K invested in REGENERX BIOPHARMACEUTICALS in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
55% more capital invested
Capital invested by funds: $31K → $48K (+$17K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Colony Group
Boston,
Massachusetts
|
+$3K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WJWM
1
Williams Jones Wealth Management
New York
| $38K | – | – | – |
|
|
DBIA
2
Dumont & Blake Investment Advisors
Princeton,
New Jersey
| $4K | – | – | – |
|
|
3
Victory Capital Management
San Antonio,
Texas
| $3K | +$3K | +13,440 | New |
|
|
CG
4
Colony Group
Boston,
Massachusetts
| $3K | +$3K | +15,000 | New |
|
RGN Hedge Fund Activity: Q1 2020 in Review
4 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q1 2020, worth a combined $48K — up 55% from $31K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new RGN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Colony Group, opening a new position worth an estimated $3K.
- 4 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q1 2020, up from 2 in Q4 2019.
- Funds reported $48K of REGENERX BIOPHARMACEUTICALS stock for Q1 2020, up 55% quarter-over-quarter.
- 2 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q1 2020 and 0 closed out, a net change of +2 holders.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q1 2020 was Colony Group, an estimated $3K added.
Based on aggregated 13F filings for Q1 2020.